Exact Mass: 505.2213
Exact Mass Matches: 505.2213
Found 323 metabolites which its exact mass value is equals to given mass value 505.2213
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Amprenavir
Amprenavir is only found in individuals that have used or taken this drug. It is a protease inhibitor used to treat HIV infection.Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AE - Protease inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D000995 - Antitubercular Agents D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
Benidipine
Asp Thr Arg Asp
Glu Ser Arg Asp
Arg Asp Thr Asp
Amprenavir
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AE - Protease inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D000995 - Antitubercular Agents D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
Benidipine
C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects > C08CA - Dihydropyridine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Ala Glu Thr Trp
Ala Glu Trp Thr
Ala Thr Glu Trp
Ala Thr Trp Glu
Ala Trp Glu Thr
Ala Trp Thr Glu
Cys Met Pro Arg
Cys Met Arg Pro
Cys Pro Met Arg
Cys Pro Arg Met
Cys Arg Met Pro
Cys Arg Pro Met
Asp Asp Arg Thr
Asp Asp Thr Arg
Asp Glu Arg Ser
Asp Glu Ser Arg
Asp Phe Pro Gln
Asp Phe Gln Pro
Asp Ile Met Gln
Asp Ile Gln Met
Asp Leu Met Gln
Asp Leu Gln Met
Asp Met Ile Gln
Asp Met Leu Gln
Asp Met Gln Ile
Asp Met Gln Leu
Asp Pro Phe Gln
Asp Pro Gln Phe
Asp Gln Phe Pro
Asp Gln Ile Met
Asp Gln Leu Met
Asp Gln Met Ile
Asp Gln Met Leu
Asp Gln Pro Phe
Asp Arg Asp Thr
Asp Arg Glu Ser
Asp Arg Ser Glu
Asp Arg Thr Asp
Asp Ser Glu Arg
Asp Ser Arg Glu
Asp Ser Val Trp
Asp Ser Trp Val
Asp Thr Asp Arg
Asp Val Ser Trp
Asp Val Trp Ser
Asp Trp Ser Val
Asp Trp Val Ser
Glu Ala Thr Trp
Glu Ala Trp Thr
Glu Asp Arg Ser
Glu Asp Ser Arg
Glu Phe Asn Pro
Glu Phe Pro Asn
Glu Ile Met Asn
Glu Ile Asn Met
Glu Leu Met Asn
Glu Leu Asn Met
Glu Met Ile Asn
Glu Met Leu Asn
Glu Met Asn Ile
Glu Met Asn Leu
Glu Met Gln Val
Glu Met Val Gln
Glu Asn Phe Pro
Glu Asn Ile Met
Glu Asn Leu Met
Glu Asn Met Ile
Glu Asn Met Leu
Glu Asn Pro Phe
Glu Pro Phe Asn
Glu Pro Asn Phe
Glu Gln Met Val
Glu Gln Val Met
Glu Arg Asp Ser
Glu Arg Ser Asp
Glu Ser Asp Arg
Glu Thr Ala Trp
Glu Thr Trp Ala
Glu Val Met Gln
Glu Val Gln Met
Glu Trp Ala Thr
Glu Trp Thr Ala
Phe Asp Pro Gln
Phe Asp Gln Pro
Phe Glu Asn Pro
Phe Glu Pro Asn
Phe Asn Glu Pro
Phe Asn Pro Glu
Phe Pro Asp Gln
Phe Pro Glu Asn
Phe Pro Asn Glu
Phe Pro Gln Asp
Phe Gln Asp Pro
Phe Gln Pro Asp
Ile Asp Met Gln
Ile Asp Gln Met
Ile Glu Met Asn
Ile Glu Asn Met
Ile Met Asp Gln
Ile Met Glu Asn
Ile Met Asn Glu
Ile Met Gln Asp
Ile Asn Glu Met
Ile Asn Met Glu
Ile Gln Asp Met
Ile Gln Met Asp
Leu Asp Met Gln
Leu Asp Gln Met
Leu Glu Met Asn
Leu Glu Asn Met
Leu Met Asp Gln
Leu Met Glu Asn
Leu Met Asn Glu
Leu Met Gln Asp
Leu Asn Glu Met
Leu Asn Met Glu
Leu Gln Asp Met
Leu Gln Met Asp
Met Cys Pro Arg
Met Cys Arg Pro
Met Asp Ile Gln
Met Asp Leu Gln
Met Asp Gln Ile
Met Asp Gln Leu
Met Glu Ile Asn
Met Glu Leu Asn
Met Glu Asn Ile
Met Glu Asn Leu
Met Glu Gln Val
Met Glu Val Gln
Met Ile Asp Gln
Met Ile Glu Asn
Met Ile Asn Glu
Met Ile Gln Asp
Met Leu Asp Gln
Met Leu Glu Asn
Met Leu Asn Glu
Met Leu Gln Asp
Met Asn Glu Ile
Met Asn Glu Leu
Met Asn Ile Glu
Met Asn Leu Glu
Met Pro Cys Arg
Met Pro Arg Cys
Met Gln Asp Ile
Met Gln Asp Leu
Met Gln Glu Val
Met Gln Ile Asp
Met Gln Leu Asp
Met Gln Val Glu
Met Arg Cys Pro
Met Arg Pro Cys
Met Val Glu Gln
Met Val Gln Glu
Asn Glu Phe Pro
Asn Glu Ile Met
Asn Glu Leu Met
Asn Glu Met Ile
Asn Glu Met Leu
Asn Glu Pro Phe
Asn Phe Glu Pro
Asn Phe Pro Glu
Asn Ile Glu Met
Asn Ile Met Glu
Asn Leu Glu Met
Asn Leu Met Glu
Asn Met Glu Ile
Asn Met Glu Leu
Asn Met Ile Glu
Asn Met Leu Glu
Asn Pro Glu Phe
Asn Pro Phe Glu
Pro Cys Met Arg
Pro Cys Arg Met
Pro Asp Phe Gln
Pro Asp Gln Phe
Pro Glu Phe Asn
Pro Glu Asn Phe
Pro Phe Asp Gln
Pro Phe Glu Asn
Pro Phe Asn Glu
Pro Phe Gln Asp
Pro Met Cys Arg
Pro Met Arg Cys
Pro Asn Glu Phe
Pro Asn Phe Glu
Pro Gln Asp Phe
Pro Gln Phe Asp
Pro Arg Cys Met
Pro Arg Met Cys
Gln Asp Phe Pro
Gln Asp Ile Met
Gln Asp Leu Met
Gln Asp Met Ile
Gln Asp Met Leu
Gln Asp Pro Phe
Gln Glu Met Val
Gln Glu Val Met
Gln Phe Asp Pro
Gln Phe Pro Asp
Gln Ile Asp Met
Gln Ile Met Asp
Gln Leu Asp Met
Gln Leu Met Asp
Gln Met Asp Ile
Gln Met Asp Leu
Gln Met Glu Val
Gln Met Ile Asp
Gln Met Leu Asp
Gln Met Val Glu
Gln Pro Asp Phe
Gln Pro Phe Asp
Gln Val Glu Met
Gln Val Met Glu
Arg Cys Met Pro
Arg Cys Pro Met
Arg Asp Asp Thr
Arg Asp Glu Ser
Arg Asp Ser Glu
Arg Glu Asp Ser
Arg Glu Ser Asp
Arg Met Cys Pro
Arg Met Pro Cys
Arg Pro Cys Met
Arg Pro Met Cys
Arg Ser Asp Glu
Arg Ser Glu Asp
Arg Thr Asp Asp
Ser Asp Glu Arg
Ser Asp Arg Glu
Ser Asp Val Trp
Ser Asp Trp Val
Ser Glu Asp Arg
Ser Glu Arg Asp
Ser Arg Asp Glu
Ser Arg Glu Asp
Ser Val Asp Trp
Ser Val Trp Asp
Ser Trp Asp Val
Ser Trp Val Asp
Thr Ala Glu Trp
Thr Ala Trp Glu
Thr Asp Asp Arg
Thr Asp Arg Asp
Thr Glu Ala Trp
Thr Glu Trp Ala
Thr Arg Asp Asp
Thr Trp Ala Glu
Thr Trp Glu Ala
Val Asp Ser Trp
Val Asp Trp Ser
Val Glu Met Gln
Val Glu Gln Met
Val Met Glu Gln
Val Met Gln Glu
Val Gln Glu Met
Val Gln Met Glu
Val Ser Asp Trp
Val Ser Trp Asp
Val Trp Asp Ser
Val Trp Ser Asp
Trp Ala Glu Thr
Trp Ala Thr Glu
Trp Asp Ser Val
Trp Asp Val Ser
Trp Glu Ala Thr
Trp Glu Thr Ala
Trp Ser Asp Val
Trp Ser Val Asp
Trp Thr Ala Glu
Trp Thr Glu Ala
Trp Val Asp Ser
Trp Val Ser Asp
3-(4-(N-Biotinoyl-6-aminocaproyloxy)phenyl)propionic acid
(11ar)-(+)-10,11,12,13-tetrahydrodiindeno[7,1-de:1,7-fg][1,3,2]dioxaphosphocin-5-bis(r)-1phenylethyl]amine
(1-[(9H-FLUOREN-9-YLMETHOXYCARBONYLAMINO)-METHYL]-CYCLOHEXYL)-ACETICACID
Methylstat
Methylstat is a potent histone demethylases inhibitor. Methylstat shows anti-proliferative activity with low cytotoxicity. Methylstat induces apoptosis and cell cycle arrest at G0/G1 phase. Methylstat increases the expression of p53 and p21 protein levels. Methylstat inhibits angiogenesis induced by various cytokines. Methylstat can be used as a chemical probe for addressing its role in angiogenesis[1][2].
methyl (3R,5S,7R,9R,10R)-10-[(2R,3E,5E,7Z)-7-(2,4-dioxopyrrolidin-3-ylidene)-7-hydroxy-4-methylhepta-3,5-dien-2-yl]-7-hydroxy-3,5,9-trimethyl-4,11,12-trioxatricyclo[6.3.1.01,5]dodecane-2-carboxylate
5-O-[(3R)-1-benzylpiperidin-3-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
N-[[(2S,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
5-O-[(3R)-1-benzylpiperidin-3-yl] 3-O-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-3,4-dihydropyridine-3,5-dicarboxylate
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[[(2R,3R)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2R,3S)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2R,3R)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2S,3R)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
4-methoxy-N-[(4R,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzenesulfonamide
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]methanesulfonamide
N-[[(2S,3S)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2R,3R)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2S,3S)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2R,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2R,3R)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2R,3S)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
BAN ORL 24
BAN ORL 24 is a nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) antagonist. BAN ORL 24 has antagonistic effect for nociceptin (NOP) receptor with KI value of 0.24 nM in CHO cell. BAN ORL 24 can be used for the research of cancer and analgesic[1].